[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[PVS] Biomarkers Conference



=============================================================
Biomarkers 2008
Discovery, Validation and Application of Biomarker Technology
=============================================================
17TH – 19TH MARCH 2008, LONDON, UK

Industry leaders you will meet at the event include:
- Dr Hans Winkler, Senior Director, Translational Research Oncology, Johnson and Johnson
- Dr Paul Whiting, Head of Biomarkers & Translational Biology, Pfizer*
- Professor Ian Wilson, Senior Principal Scientist, AstraZeneca
- Andrew Doherty, Director of Research Alliances, UCB*
- Dr Christian Czech, CNS Research, Roche
- Dr Dave Moskowitz, CEO, Genomed
- Anna Rossi, Section Head, Toxicology & Drug Disposition, Organon*
- Alastair Kent, Director, Genetic Interest Group
- Dr Alison Banham, Nuffield Department of Clinical Laboratory Sciences, University of Oxford
- Professor William M. Gallagher, Associate Professor of Cancer Biology, UCD Conway Institute, University College Dublin, Co-Founder, OncoMark Limited
- Dr Piotr Lewczuk , Molecular Neurobiology Lab, Department of Psychiatry and. Psychotherapy  University of Erlangen-Nuremberg
* to be confirmed

Reasons you cannot afford to miss this event:
- Identify areas where biomarker technology can increase the efficiency of your clinical trial process.
- Understand the potential for biomarkers in developing personalised medicine. How will this change the existing big pharma business model? Prepare your business to more fully integrate these operational and organisational changes.
- Discuss the latest biomarker assay developments and methods of clinical validation.
- Gain a deeper understanding of the growing biomarker industry. Who are the key players? What are the next developments? Where can you make the best alliance?

The pharmaceutical industry is constantly looking for ways to cut costs, speed drugs to market and develop innovative new products to improve patient care. Biomarker technology can help your company achieve these three key goals. Yet despite the benefits biomarker technology has the potential to accrue, it is not yet widely applied. Successful application could give your company the competitive advantage it seeks, and this conference will help identify areas where biomarkers can be implemented in your business practices.

As the traditional blockbuster business model falters in its tracks, recently illustrated by Pfizer’s difficulties with Exubera, it seems the industry is shifting towards portfolios of personalised medicines. These can only be developed with the aid of biomarkers.

It is a new and exciting technology, which still has a lot of scope for innovative business applications. Methods of discovery are constantly evolving; as scientists begin to fully understand the potential of genomics, the whole scope of proteome analysis opens up before them. Applications for these new discoveries are still being explored and a major challenge is now faced in convincing the regulators.

This three day Visiongain conference will explore the business applications and regulatory considerations necessary for you to realise the potential biomarkers have for your business.

======================================================
Plus interactive 1-day workshop
Implementing gene expression based drug response profiling in clinical trials
Led by: Bastiaan van der Baan, Director, Business Development, Agendia
======================================================

- Booking your place -
- 3 day Conference and Workshop ticket - available for only GBP£1699
- 2 day Conference only ticket - available for only GBP £1299
If you would like to send more than 1 person then take advantage of the 3 for 2 offer. Send 3 people but only pay for 2. Excellent networking opportunities.

- How to book -
Ordering is simple! All you need to do to book your place is contact Natalia Fontao. You can either call me on TEL: +44 (0)207 549 9971 or email mailto: pharma.reports1@visiongaingroup.com.
Please feel free to contact me should you have any questions, or wish to purchase a place.

Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have
a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.

If you would like more information on the range of sponsorship or exhibition possibilities, please contact:  Natalia Fontao, Tel:+44 (0)20 7549 9971, Email: pharma.reports1@visiongaingroup.com

 
I look forward to meeting you at the conference

Kind Regards,

Natalia Fontao
Visiongain Ltd.
4th Floor,
BSG House,
226-236 City Road,
London
EC1V 2QY
United Kingdom


Conference Agenda
09:30 Registration and refreshments

10:00 Opening address from the chair
Dr Dave Moskowitz, CEO, Genomed

10:10 Adapting your business for biomarkers
• Does the use of biomarkers herald the end of the blockbuster drug model?
• Adjusting your business
 - New roles
 - Governance structures
• Overcoming the traditional attitudes to phase differentiation
Dr Paul Whiting, Head of Biomarkers & Translational Biology, Pfizer*

10:50 Outsourcing biomarker research
• External partnerships vs internal capabilities
• Choosing where to outsource
 - What to look for in a partner
 - Planning division of responsibility
• Collaborating with academia
Andrew Doherty, Director of Research Alliances, UCB*

11:30 Morning refreshments

11:50 Utilising bioinformatics in biomarker discovery
• Developing a ‘fit-for-purpose’ system
• Ensuring statistical value and avoiding false discovery rates
• Setting meaningful thresholds for identification

12:30 Quantitative, specific and spatial identification of protein modifications as biomarkers
• Targeted therapeutics directed at signalling pathways demand specific biomarker readouts
• The specificity of reagents employed to interrogate signalling pathways by immunohistochemistry is typically inadequate
• There is a need for quantitative and spatially resolved biomarker readouts
Professor Peter Parker, Head of The Division of Cancer Studies, King’s College London

13:00 Networking lunch

14:20 Predispostion SNPs: Biomarkers of choice
• Genetic statisticians vs genomic epidemiologists
• The failure of ‘neutral markers’ to fund success with any polygenic disease
• The successes of functional SNP markers
• Identification of genes in the earliest stages of tumorigenesis
• Identifying the earliest circulating markers in the disease process
Dr Dave Moskowitz, CEO, Genomed

15:00 Application of metabolic profiling in biomarker discovery
• Metabolites as biomarkers of disease, efficacy and toxicity.
• Methodologies for profiling and biomarker discovery
• Animal model to clinical trial - applications and challenges
• Gaining new insights - metabolites to systems.
Professor Ian Wilson, Senior Principal Scientist, AstraZeneca

15:40 Afternoon refreshments

16:00 Developing safe and effective therapies for unmet medical needs
• Participation of patients and families in the process of undertaking clinical research
• The selection of relevant endpoints – what are the risks and benefits?
• Using biomarkers as a staging post in the development of safe and effective therapies for unmet medical needs – the perspective of patients and their families
Alastair Kent, Director, Genetic Interest Group

16:40 Translating patient selection markers for clinical application
• Discovery of markers for selection of patients with increased likelihood to benefit from treatment
• Assay development
• Assessment of clinical utility
• Application for streamlining early clinical development
• Development of theranostics
Dr Hans Winkler, Senior Director, Translational Research Oncology, Johnson and Johnson

17:20 Closing remarks from the chair

17:30 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.

Day Two
09:30 Registration and refreshments

10:00 Opening address from the chair
Dr Dave Moskowitz, CEO, Genomed

10:10 Identification, validation and application of efficacy biomarkers in the development of novel anti-cancer agents
• Biomarker identification. Screening using available antibodies and the utility of mass spectrometry in the absence of good antibodies
• Development of assays to measure these biomarkers in pre-clinical cancer models using a range of platforms
• Translating these assays for clinical usage. The utility of surrogate versus diseased tissue
Speaker to be announced

10:50 Identification and validation of novel lymphoma biomarkers
• The clinical need for additional lymphoma biomarkers
• Diagnostic biomarkers to define disease subtypes and facilitate early diagnosis
• Prognostic markers to identify high-risk patients
• Biomarkers as therapeutic targets
• The relevance of lymphoma biomarkers in other malignancies
Dr Alison Banham, Nuffield Department of Clinical Laboratory Sciences, University of Oxford

11:30 Morning refreshments

11:50 Tissue microarray and digital slide scanning technology: application to cancer and toxicological biomarker development
• Tissue microarrays as translational research tools
• Bridging from discovery to validation in the omic era
• Manual and automated image analysis
• Case studies in cancer and toxicology
Professor William M. Gallagher, Associate Professor of Cancer Biology, UCD Conway Institute, University College Dublin, Co-Founder, OncoMark Limited

12:30 Use of biomarkers for safety assessment
• Validating toxicity biomarkers
• Detecting toxicity at a lower concentrations earlier on
• Using biomarkers to create an effective dosing regime at an earlier stage of clinical trials
• Improving pharmacovigilence
Anna Rossi, Section Head, Toxicology & Drug Disposition, Organon*

13:10 Networking lunch

14:30 Neurochemical dementia diagnostics: state of the art and research perspectives

• Current routine CSF-based NDD,
Perspectives of dementia biomarkers research:
- Novel biomarkers for Alzheimer’s disease
- Possibilities of differential diagnostics among dementia disorders (CJD, DLB, etc.)
- Improvement of the performance of the available biomarkers
- Application of novel technologies (multiplexing, etc.)
- Biomarkers in blood
Dr Piotr Lewczuk , Molecular Neurobiology Lab, Department of Psychiatry and. Psychotherapy
University of Erlangen-Nuremberg

15:10 Biomarker for Alzheimer’s disease: strategy for identification and validation of new markers
• Targets and models for disease modification in Alzheimer’s disease
• Technologies for biomarker identification
• Strategies for biomarker validation
• Biochemical markers for diagnosis and disease progression in Alzheimer’s disease
Dr Christian Czech, CNS Research, Roche

15:50 Afternoon refreshments

16:10 Presentation to be announced

16.50 Panel Discussion: What does the future hold for biomarker technology?
• How will advances in proteomics affect biomarkers? Will it overtake genetic methods of biomarker discovery?
• Repositioning drugs on the market; what are the longer term industry implications?
• Moving towards personalized medicine

17:30 Chair’s closing remarks

17:40 End of conference

- Booking your place -
- 3 day Conference and Workshop ticket - available for only GBP£1699
- 2 day Conference only ticket - available for only GBP £1299
If you would like to send more than 1 person then take advantage of the 3 for 2 offer. Send 3 people but only pay for 2. Excellent networking opportunities.

- How to book -
Ordering is simple! All you need to do to book your place is contact Natalia Fontao now. You can either call me on TEL: +44 (0)207 549 9971 or email mailto: pharma.reports1@visiongaingroup.com


Upcoming Conferences:
Please, note we have many events taking place in the next months. If you are interested in one of them, do not hesitate to contact me.
_4th Annual Advances in Diabetic Therapeutics 18th - 20th February 2008, London
_Biomarkers 2008 17th -19th March 2008, London
_4th Monoclonal Antibodies in Therapeutics 27th -28th March, London
_Clinical Trials Awards & Conference 9th - 11th April 2008, London
_Dissolution Testing, Bioequivalence and Bioavailability Strategies 19th - 21st May 2008, London
_7th Pricing & Reimbursement 11th -13th June 2008, London
_4th Biosimilars 18th - 20th June 2008, USA
_3rd Annual Pharmacovigilance 9th- 11th Ju! ly 2008, London

Please feel free to contact me should you have any questions, or wish to purchase a place, I look forward to hearing from you.


Kind Regards,

Natalia Fontao. 
Visiongain Ltd.
4th Floor,
BSG House,
226-236 City Road,
London
EC1V 2QY
United Kingdom

 


If, however, you do not wish to receive future messages, please reply to this message, typing 'unsubscribe' in the subject box of your email.

Terms & Conditions

NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or ! after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditi! ons, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.

Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you maybe used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may share your data with external companies offering complimentary products or services. If you wish your details to be amended, suppressed or not passed onto any external third party, please send your request to the Database Manager, visiongain Ltd